Markets have become so stretched in one direction that a simple -1% drop in $QQQ is enough to send the whole Managed Care complex +5%; Factor investing at a glance. Basically everything has become a funding short for $QQQ and $SOXX.
CME CEO Duffy on perpetual futures coming to the US: “I don’t want to see retail get destroyed after we have spent many years educating them”
It is an incredible how much of a lead CME had in innovating around derivatives. They sat on their money printing machine for decades and did not innovate.
Even if you guard rail the product from retail, why not offer it to the experienced traders who want this? There is clearly demand for it in a free market
A friendly reminder about comparing today to 2000. The Fed was raising rates from June 1999, culminating in a 50-basis point increase in May 2000. TIPS yielded over 4% vs 2.6% today. Fed Fund were > 6.5% vs 3.5% today. There is nothing stopping this market from going to CAPE 50, 60, 70.
@irbezek@RoadieWolf And I know it was the hotel because I didn’t use that card anywhere else. Not something that I get bend out of shape about, one call to the bank solve the problem. But clearly it can happen.
@irbezek@RoadieWolf Paid by card at a pretty nice (+1k / night) resort on Baru island, near Cartagena. Next thing I know someone is buying shoes with my card in Miami.
The selloff in the high moat, compounder names is getting ridiculous. The irrs I get for some of these co's as long as they don't royally shit the bed are pretty attractive. Stuff like $SPGI, $MA, $V, $BR and now add $CME, $CBOE and $ICE with their recent selloff. Steadily adding
1/ $PODD / Insulet, the tubeless insulin pump leader, sold down ~60% from its highs to near 52-week lows (~$142) while still compounding revenue 30%+. The market is pricing a device-recall scare. The business underneath is one of the cleaner recurring-revenue compounders in medtech.
7/ Bottom line: A category-leading, recurring-revenue compounder growing 25%+ has de-rated toward a market multiple on a manufacturing/quality scare the company is actively remediating. The bet: the franchise outlasts the headline. Watching execution on the corrections and margin recovery. Long $PODD.